1. Scrip
  2. >>New Products

BMS Focuses On Driving Future Growth As Revlimid Generic Launches Near

Opdivo, Eliquis Rise From Year-Ago Quarter, But Down From Q2

 
• By Mandy Jackson

New product sales doubled from $161m in the first quarter to $344m in Q3 and the R&D pipeline advancing as planned ahead of generic competition for Revlimid, which will begin to launch in 2022.

Business investment growth concept with abstract arrows on building
Total third quarter revenue of $11.6bn was up 10% from Q3 2020 • Source: Alamy

Bristol Myers Squibb Company reported $11.6bn in third quarter revenue that exceeded analyst consensus on 27 October, driven in part by newer product sales, which more than doubled from Q1 to Q3. The company, under pressure to produce significant revenue growth before mega-blockbuster Revlimid (lenalidomide) begins to face loss of exclusivity next year, also largely has seen success in its research and development pipeline since acquiring Celgene Corporation at the end of 2019 despite some initial stumbles.

Volume-limited Revlimid generics will begin to launch in the US in 2022 along with generics in some ex-US markets. The Celgene acquisition brought the multiple myeloma drug – now...

Q3 New Product Sales

  • Reblozyl, $160m in Q3, up 67% from $96m in Q3 2020

  • Inrebic, $22m, up 69% year-over-year from $13m

  • Onureg, $21m versus $3m...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By Kevin Grogan

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

Pipeline Watch: 12 Approvals And 26 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

More from Scrip

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback